Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05323409 · ClinicalTrials.gov registry record · NA
Improving Comprehensive Care of Cancer Patients
A NA study of Breast Cancer and Gastrointestinal Cancer, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 340
- Enrollment target
- 1
- Study location
NCT05323409 is a NA study of Breast Cancer and Gastrointestinal Cancer that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 340 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05323409, a NA study of Breast Cancer and Gastrointestinal Cancer, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
- 1
- Study location
Study Summary
Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Medically underserved patients, who bear the highest burden of multiple chronic conditions, are at increased risk for poor outcomes during and after cancer treatment. Enhancing communication and collaboration between oncologists and primary care providers (PCPs) could improve health outcomes and care transitions for these patients, who often lack healthcare knowledge and access to supportive care. This study evaluates a novel shared care model for cancer survivors with chronic comorbidities, called OPTIMISE (Oncology-Primary Care Partnership to Improve Comprehensive Survivorship Care), in the largest safety-net healthcare system in Houston, Texas. Three hundred newly diagnosed breast, gastrointestinal, and hematological cancer patients being treated with curative intent and having comorbidities requiring ongoing management will be randomized to either OPTIMISE or Usual Medical Care (UMC). UMC patients will receive cancer treatment directed by their oncologist, a survivorship care plan (SCP) at the end of active treatment, and surveillance visits based on national guidelines. OPTIMISE patients will: 1) have an oncology nurse navigator assigned to their care team at diagnosis to facilitate oncologist-PCP communication; 2) receive coordinated care between their oncologist and PCP throughout cancer treatment and surveillance, facilitated by structured communication and referral processes; 3) receive an SCP that incorporates comorbidity management; and 4) follow a risk-stratified shared care model where some routine oncologist follow-up visits are replaced by PCP visits. Aim 1a evaluates OPTIMISE's impact on patient chronic disease self-m
Conditions Studied
Interventions
- BEHAVIORAL OPTIMISE
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05323409
The ClinicalTrials.gov registry entry for NCT05323409 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which OPTIMISE is the first listed.
NCT05323409 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05323409 about?
NCT05323409 is a clinical study titled "Improving Comprehensive Care of Cancer Patients". Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates ...
What is the current status of trial NCT05323409?
This trial is currently recruiting. It is a NA study. The enrollment target is 340 participants. The study started on 2022-04-01. Estimated completion is 2026-06.
What conditions does trial NCT05323409 study?
This clinical trial studies the following conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer.
What interventions are being tested in trial NCT05323409?
The interventions under investigation include: OPTIMISE (BEHAVIORAL).
Who is sponsoring clinical trial NCT05323409?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05323409 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.